Medpace Holdings, Inc. (MEDP)
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
- Ticker
- MEDP
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Market cap
- $18.27B
- 52-week range
- $373.00 - $693.97
Valuation
- Share price
- $653.11 (close of Nov 6, 2026)
- P/E (TTM)
- 35.57x
- Price to book
- 31.23x
- Price to free cash flow
- 27.36x
- Enterprise value
- $17.71B
- Book value per share
- $20.92
Price performance
| Period | Change |
|---|---|
| 1 day | +2.86% |
| 5 days | +0.17% |
| 1 month | +8.33% |
| 3 months | +11.64% |
| 6 months | +53.03% |
| Year to date | +16.28% |
| 1 year | +10.29% |
| 3 years | +142.46% |
| 5 years | +189.19% |
| 10 years | +2,008.85% |
| All time | +2,250.16% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 7.09%
- Shares short
- 1.61M
- Days to cover
- 6.59
- Change since prior report
- +1.01%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed MEDP trades
David Taylor · Gilbert Ray Cisneros · Lisa McClain · Robert Bresnahan
Super investors holding MEDP
Francois Rochon (Giverny Capital Inc) · Vulcan Value Partners (Vulcan Value Partners, LLC) · Mairs & Power (Mairs & Power Inc) · Terry Smith (Fundsmith LLP) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- 98.27%
- Return on invested capital
- 77.47%
- Return on assets
- 22.84%
- Return on capital employed
- 84.68%
- Gross margin
- 30.06%
- Net margin
- 17.83%
- EBITDA margin
- 22.25%
- Revenue growth
- 19.97%
- Net income growth
- 11.56%
- Free cash flow growth
- 19.15%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 3.66%
- Current ratio
- 0.83x
- Net debt to EBITDA
- -0.88x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $2.53B
- Cost of revenue
- $1.77B
- Gross profit
- $760.62M
- EBITDA
- $563.06M
- Net income
- $451.12M
- Earnings per share
- $15.64
- Shares outstanding
- 28.85M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $2.53B | $760.62M | $451.12M | $15.64 |
| 2024-12-31 | $2.11B | $656.30M | $404.39M | $13.06 |
| 2023-12-31 | $1.89B | $524.50M | $282.81M | $9.20 |
| 2022-12-31 | $1.46B | $432.44M | $245.37M | $7.57 |
| 2021-12-31 | $1.14B | $328.15M | $181.85M | $5.06 |
| 2020-12-31 | $925.92M | $278.73M | $145.38M | $4.07 |
| 2019-12-31 | $860.97M | $245.70M | $100.44M | $2.79 |
| 2018-12-31 | $704.59M | $215.53M | $73.19M | $2.05 |
| 2017-12-31 | $436.15M | $174.69M | $39.12M | $1.00 |
| 2016-12-31 | $421.58M | $172.11M | $13.43M | $0.38 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 30.06% | 17.83% | 98.27% | 77.47% |
| 2024-12-31 | 31.12% | 19.17% | 48.98% | 39.43% |
| 2023-12-31 | 27.81% | 15.00% | 50.60% | 40.50% |
| 2022-12-31 | 29.62% | 16.81% | 63.50% | 41.93% |
| 2021-12-31 | 28.73% | 15.92% | 19.08% | 16.23% |
| 2020-12-31 | 30.10% | 15.70% | 18.04% | 15.36% |
| 2019-12-31 | 28.54% | 11.67% | 13.83% | 13.15% |
| 2018-12-31 | 30.59% | 10.39% | 12.22% | 11.83% |
| 2017-12-31 | 40.05% | 8.97% | 7.68% | 6.44% |
| 2016-12-31 | 40.83% | 3.18% | 2.20% | 5.68% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $497.05M | - |
| 2024-12-31 | $669.44M | - |
| 2023-12-31 | $245.45M | - |
| 2022-12-31 | $28.27M | $50.00M |
| 2021-12-31 | $461.30M | - |
| 2020-12-31 | $277.77M | - |
| 2019-12-31 | $131.92M | - |
| 2018-12-31 | $23.27M | $79.72M |
| 2017-12-31 | $26.48M | $205.11M |
| 2016-12-31 | $37.10M | $151.27M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $681.87M | $34.79M |
| 2024-12-31 | $572.27M | $25.51M |
| 2023-12-31 | $396.73M | $20.52M |
| 2022-12-31 | $351.17M | $21.41M |
| 2021-12-31 | $235.06M | $14.47M |
| 2020-12-31 | $227.34M | $13.78M |
| 2019-12-31 | $183.96M | $20.74M |
| 2018-12-31 | $140.56M | $6.50M |
| 2017-12-31 | $85.66M | $4.46M |
| 2016-12-31 | $78.19M | $9.81M |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-21 | Sep 2026 | $4.45 |
| 2026-07-22 | Jun 2026 | $4.08 |
| 2026-04-22 | Mar 2026 | $3.74 |
| 2026-02-09 | Dec 2025 | $4.18 |
| 2025-10-22 | Sep 2025 | $3.50 |
| 2025-07-21 | Jun 2025 | $3.00 |
| 2025-04-21 | Mar 2025 | $3.06 |
| 2025-02-10 | Dec 2024 | $2.97 |
Filings and sources
- Company website
- medpace.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Revvity, Inc. (RVTY) · Labcorp Holdings Inc. (LH) · Charles River Laboratories International, Inc. (CRL) · Quest Diagnostics Inc (DGX) · ICON plc (ICLR) · Mettler-Toledo International Inc (MTD) · Illumina, Inc. (ILMN) · Waters Corp (WAT)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades